Skip to content

Multi-center clinical study on individualized medication for hypertension in Fujian Province

Multi-center clinical study on individualized medication for hypertension

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057507
Enrollment
Unknown
Registered
2022-03-14
Start date
2022-03-15
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

gene-detection group:Choosing drugs based on gene sensitivity of hypertension drugs
evidence-based group:Choose antihypertensive drugs according to evidence-based medical evidence

Sponsors

The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Patients diagnosed as grade 1-2 essential hypertension; 3. Willing to undergo follow-up and observation; 4. Clearly understand and voluntarily participate in the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. More than 3 kinds of antihypertensive drugs have been used; 2. Diabetic patients who have used hypoglycemic drugs; 3. Heart rate <=55 beats/min, malignant tumor; 4. Combined with liver and kidney insufficiency; 5. Severe heart failure, EF<35%; 6. Coronary heart disease, stroke; 7. Severe trauma and major surgery; 8. Pregnant or lactating patients, patients who cannot take contraceptive measures during the reproductive period.

Design outcomes

Primary

MeasureTime frame
blood pressure;

Secondary

MeasureTime frame
liver function;adverse drug reaction;renal function;

Countries

China

Contacts

Public ContactLuo Li

The First Affiliated Hospital of Fujian Medical University

hluoli@126.com+86 13358220810

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026